Stocklore

Abbott Laboratories (ABT)

Biotech & Health · US stock

What changed this quarter

  • Risk factors — 1 added · 2 removed · new: Changes in geopolitical and macroeconomic c…

What changed in recent SEC filings — factual, not a buy/sell recommendation.

Company overview

Abbott Laboratories. A healthcare conglomerate running medical devices (the FreeStyle Libre glucose sensor), diagnostics, and nutrition.

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

Abbott Laboratories is classified under the Biotech & Health sector. See peers below.

Abbott Laboratories key financials

Based on SEC filings · latest quarter (TTM)

Tap a metric name to see its meaning in the glossary.

ETFs holding Abbott Laboratories

Per SEC N-PORT · 2026-03-31 · by weight · factual

XLVState Street(R) Health Care Select Sector SPDR(R) ETF
3.37%
VYMVANGUARD HIGH DIVIDEND YIELD INDEX FUND
0.65%
VOOVANGUARD 500 INDEX FUND
0.32%
SPY
0.32%
IVViShares Core S&P 500 ETF
0.32%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
0.28%
ITOTiShares Core S&P Total U.S. Stock Market ETF
0.28%
RSPInvesco S&P 500 Equal Weight ETF
0.17%

ABT on Stocklore

  • Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
  • Sector-relative metrics — valuation and growth vs the Biotech & Health average
See full ABT analysis →

Peers · Biotech & Health

ABT FAQ

What is Abbott Laboratories (ABT)?

Abbott Laboratories. A healthcare conglomerate running medical devices (the FreeStyle Libre glucose sensor), diagnostics, and nutrition.

What sector is Abbott Laboratories in?

Abbott Laboratories is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

What are Abbott Laboratories's key financials?

Based on the latest quarter (TTM) from SEC filings: Revenue growth (YoY) 6.6%, Operating margin 12.0%, Net margin 13.9%, ROE 12.5%, Debt-to-equity 0.25x. Definitions and interpretation are available on Stocklore.

Where can I analyze Abbott Laboratories (ABT) stock?

On Stocklore you can see ABT's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

Stocklore · CEO Lee Seung-jae · Business reg. no. 764-36-01607 · E-commerce permit 2026-Jeonju Wansan-0476 · Tel +82-70-7954-4939 · S120, Rm 302, 3F, 21 Jungsanjungang-ro, Wansan-gu, Jeonju, Jeonbuk, Korea